Accreditation for this course expired on December 27th, 2022. If you would still like an activity completion certificate, send your request to email@example.com.
This case study features expert discussion surrounding a real HCM patient and is designed to raise disease awareness and provide you with an understanding of the risk factors for sudden cardiac death in pediatric HCM patients. It assists clinicians in community practice or those with an interest in HCM management to:
- recognize major risk factors for sudden cardiac death in pediatric HCM patients
- understand the differences in risk stratification in pediatric and adult patients
- know when referral to an HCM expert center is appropriate
This case study discussion is designed to be completed in 45 minutes
Target audience: Family / general physicians, general / community cardiologists, cardiac nurses, pediatricians, pediatric nurses, genetic counselors
Funding disclosure: This activity is supported by educational grant funding from BMS, Cytokinetics and Sanofi.
Learners may participate in this educational activity free of charge.
- Sudden cardiac death and major risk factors in adult HCM patients
- Major risk factors in pediatric HCM patients
- Reducing SCD risk
- ICD recommendations
By the end of this activity, learners will be able to:
- Recall the limitations of implantable cardioverter-defibrillators (ICD) available for sudden cardiac death (SCD) prevention and how they relate to pediatric patients
- List the risk factors that should be considered for pediatric SCD risk assessment and apply these to example data
- Outline the patient factors to appraise when considering ICD implantation in a pediatric patient and apply these to a sample patient
- Recall how septal z-scores are used in evaluating HCM in pediatric patient
- Outline the potential benefits to patients of referral to an HCM Center of Excellence
Accreditation for this course has expired. You may view the program, but CME / CE is no longer available and no certificate will be issued.
Dr John Lynn Jefferies, MD, Professor and Chief of Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease, Methodist University Hospital/ University of Tennessee, St Jude Children’s Research Hospital, has received financial compensation for consulting for Abbott, Novartis, and Pfizer, and received research grants from Myokardia, Abbott, Novartis, and Pfizer.
Dr Martin Maron, MD, Director of the Hypertrophic Cardiomyopathy Center and Research Institute at Tufts Medical Center and the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center, has received financial compensation for consulting for Cytokinetics and Imbria, and received research grants from Takeda and iRhythm.
Disclosure of educational planners:
Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.
Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
All relevant financial relationships have been mitigated.